Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 3, 2025Frontiers in OncologyOpen Access

Treatment efficacy of first-line immunotherapy in advanced esophageal small cell carcinoma: A real-world retrospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

NLNan LiRZRui Zhang

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows longer progression-free survival with immunotherapy plus chemotherapy in SCCE patients, suggesting improved treatment outcomes.

Key Points

  • Patients receiving first-line immunotherapy plus chemotherapy had a median progression-free survival of 10.0 months.
  • The median progression-free survival for chemotherapy alone was 3.2 months, indicating a significant impact of immunotherapy.
  • Statistical analysis showed that immunotherapy may improve prognosis compared to treatment without it.
  • This study suggests combining immunotherapy with chemotherapy could be beneficial for advanced esophageal small cell carcinoma patients.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/68e02f2cf0e39f13e7fa1eb6https://doi.org/10.3389/fonc.2025.1630210
View Full Paper
Ask AI
Bookmark
Share